Long-term Results after Oncoplastic Surgery for Breast Cancer: A 10-year Follow-up

Krishna B. Clough, Raquel F.D. Van La Parra, Helene H. Thygesen, Eric Levy, Elisabeth Russ, Najeeb Halabi, Isabelle Sarfati, Claude Nos

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: The aim of this study was to evaluate the long-term oncologic outcome after oncoplastic surgery (OPS). Background: OPS combines wide tumor excision with reduction mammoplasty techniques thus extending breast conserving surgery to large tumors that might else be proposed a mastectomy. Little data are available about the oncologic results for breast conserving surgery of these larger tumors. Methods: From January 2004 until March 2016, a total of 350 oncoplastic breast reductions were prospectively entered into a database. Patients were included if their breast reshaping included a reduction mammoplasty with skin excision (Level 2 oncoplastic techniques). Results: Histologic subtypes were: invasive ductal carcinoma in 219 cases (62.6%), ductal carcinoma in situ (DCIS) in 88 cases (25.1%), and invasive lobular carcinoma in 43 (12.3%) cases. Seventy-three of the invasive cancers (27.9%) received neoadjuvant chemotherapy. The mean resection weight was 177 grams. The mean pathological tumor size was 26 mm (range 0-180 mm) and varied from 23 mm (4-180 mm) for invasive cancers to 32 mm (0-100 mm) for DCIS. Specimen margins were involved in 12.6% of the cases; 10.5% of invasive ductal, 14.7% of DCIS, and 20.9% of invasive lobular. The overall breast conservation rate was 92% and varied from 87.4% for DCIS to 93.5% for the invasive cancers. Thirty-one patients (8.9%) developed one or more postoperative complications, inducing a delay in postoperative treatments in 4.6% of patients. The median follow up was 55 months. The cumulative 5-year incidences for local, regional, and distant recurrences were 2.2%, 1.1%, and 12.4%, respectively. Conclusions: Oncoplastic breast reductions allow wide resections with free margins and can be used for large cancers as an alternative to mastectomy.

Original languageEnglish
Pages (from-to)165-171
Number of pages7
JournalAnnals of Surgery
Volume268
Issue number1
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint

antineoplaston A10
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Neoplasms
Breast
Segmental Mastectomy
Mammaplasty
Mastectomy
Lobular Carcinoma
Ductal Carcinoma
Databases
Weights and Measures
Recurrence
Drug Therapy
Skin
Incidence

Keywords

  • breast cancer
  • breast conserving surgery
  • complications
  • local recurrence
  • oncoplastic surgery
  • survival
  • therapeutic mammoplasty
  • treatment delay

ASJC Scopus subject areas

  • Surgery

Cite this

Clough, K. B., Van La Parra, R. F. D., Thygesen, H. H., Levy, E., Russ, E., Halabi, N., ... Nos, C. (2018). Long-term Results after Oncoplastic Surgery for Breast Cancer: A 10-year Follow-up. Annals of Surgery, 268(1), 165-171. https://doi.org/10.1097/SLA.0000000000002255

Long-term Results after Oncoplastic Surgery for Breast Cancer : A 10-year Follow-up. / Clough, Krishna B.; Van La Parra, Raquel F.D.; Thygesen, Helene H.; Levy, Eric; Russ, Elisabeth; Halabi, Najeeb; Sarfati, Isabelle; Nos, Claude.

In: Annals of Surgery, Vol. 268, No. 1, 01.07.2018, p. 165-171.

Research output: Contribution to journalArticle

Clough, KB, Van La Parra, RFD, Thygesen, HH, Levy, E, Russ, E, Halabi, N, Sarfati, I & Nos, C 2018, 'Long-term Results after Oncoplastic Surgery for Breast Cancer: A 10-year Follow-up', Annals of Surgery, vol. 268, no. 1, pp. 165-171. https://doi.org/10.1097/SLA.0000000000002255
Clough, Krishna B. ; Van La Parra, Raquel F.D. ; Thygesen, Helene H. ; Levy, Eric ; Russ, Elisabeth ; Halabi, Najeeb ; Sarfati, Isabelle ; Nos, Claude. / Long-term Results after Oncoplastic Surgery for Breast Cancer : A 10-year Follow-up. In: Annals of Surgery. 2018 ; Vol. 268, No. 1. pp. 165-171.
@article{24f5eeb0a0174f3e80265be4fc358f97,
title = "Long-term Results after Oncoplastic Surgery for Breast Cancer: A 10-year Follow-up",
abstract = "Objective: The aim of this study was to evaluate the long-term oncologic outcome after oncoplastic surgery (OPS). Background: OPS combines wide tumor excision with reduction mammoplasty techniques thus extending breast conserving surgery to large tumors that might else be proposed a mastectomy. Little data are available about the oncologic results for breast conserving surgery of these larger tumors. Methods: From January 2004 until March 2016, a total of 350 oncoplastic breast reductions were prospectively entered into a database. Patients were included if their breast reshaping included a reduction mammoplasty with skin excision (Level 2 oncoplastic techniques). Results: Histologic subtypes were: invasive ductal carcinoma in 219 cases (62.6{\%}), ductal carcinoma in situ (DCIS) in 88 cases (25.1{\%}), and invasive lobular carcinoma in 43 (12.3{\%}) cases. Seventy-three of the invasive cancers (27.9{\%}) received neoadjuvant chemotherapy. The mean resection weight was 177 grams. The mean pathological tumor size was 26 mm (range 0-180 mm) and varied from 23 mm (4-180 mm) for invasive cancers to 32 mm (0-100 mm) for DCIS. Specimen margins were involved in 12.6{\%} of the cases; 10.5{\%} of invasive ductal, 14.7{\%} of DCIS, and 20.9{\%} of invasive lobular. The overall breast conservation rate was 92{\%} and varied from 87.4{\%} for DCIS to 93.5{\%} for the invasive cancers. Thirty-one patients (8.9{\%}) developed one or more postoperative complications, inducing a delay in postoperative treatments in 4.6{\%} of patients. The median follow up was 55 months. The cumulative 5-year incidences for local, regional, and distant recurrences were 2.2{\%}, 1.1{\%}, and 12.4{\%}, respectively. Conclusions: Oncoplastic breast reductions allow wide resections with free margins and can be used for large cancers as an alternative to mastectomy.",
keywords = "breast cancer, breast conserving surgery, complications, local recurrence, oncoplastic surgery, survival, therapeutic mammoplasty, treatment delay",
author = "Clough, {Krishna B.} and {Van La Parra}, {Raquel F.D.} and Thygesen, {Helene H.} and Eric Levy and Elisabeth Russ and Najeeb Halabi and Isabelle Sarfati and Claude Nos",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/SLA.0000000000002255",
language = "English",
volume = "268",
pages = "165--171",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Long-term Results after Oncoplastic Surgery for Breast Cancer

T2 - A 10-year Follow-up

AU - Clough, Krishna B.

AU - Van La Parra, Raquel F.D.

AU - Thygesen, Helene H.

AU - Levy, Eric

AU - Russ, Elisabeth

AU - Halabi, Najeeb

AU - Sarfati, Isabelle

AU - Nos, Claude

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objective: The aim of this study was to evaluate the long-term oncologic outcome after oncoplastic surgery (OPS). Background: OPS combines wide tumor excision with reduction mammoplasty techniques thus extending breast conserving surgery to large tumors that might else be proposed a mastectomy. Little data are available about the oncologic results for breast conserving surgery of these larger tumors. Methods: From January 2004 until March 2016, a total of 350 oncoplastic breast reductions were prospectively entered into a database. Patients were included if their breast reshaping included a reduction mammoplasty with skin excision (Level 2 oncoplastic techniques). Results: Histologic subtypes were: invasive ductal carcinoma in 219 cases (62.6%), ductal carcinoma in situ (DCIS) in 88 cases (25.1%), and invasive lobular carcinoma in 43 (12.3%) cases. Seventy-three of the invasive cancers (27.9%) received neoadjuvant chemotherapy. The mean resection weight was 177 grams. The mean pathological tumor size was 26 mm (range 0-180 mm) and varied from 23 mm (4-180 mm) for invasive cancers to 32 mm (0-100 mm) for DCIS. Specimen margins were involved in 12.6% of the cases; 10.5% of invasive ductal, 14.7% of DCIS, and 20.9% of invasive lobular. The overall breast conservation rate was 92% and varied from 87.4% for DCIS to 93.5% for the invasive cancers. Thirty-one patients (8.9%) developed one or more postoperative complications, inducing a delay in postoperative treatments in 4.6% of patients. The median follow up was 55 months. The cumulative 5-year incidences for local, regional, and distant recurrences were 2.2%, 1.1%, and 12.4%, respectively. Conclusions: Oncoplastic breast reductions allow wide resections with free margins and can be used for large cancers as an alternative to mastectomy.

AB - Objective: The aim of this study was to evaluate the long-term oncologic outcome after oncoplastic surgery (OPS). Background: OPS combines wide tumor excision with reduction mammoplasty techniques thus extending breast conserving surgery to large tumors that might else be proposed a mastectomy. Little data are available about the oncologic results for breast conserving surgery of these larger tumors. Methods: From January 2004 until March 2016, a total of 350 oncoplastic breast reductions were prospectively entered into a database. Patients were included if their breast reshaping included a reduction mammoplasty with skin excision (Level 2 oncoplastic techniques). Results: Histologic subtypes were: invasive ductal carcinoma in 219 cases (62.6%), ductal carcinoma in situ (DCIS) in 88 cases (25.1%), and invasive lobular carcinoma in 43 (12.3%) cases. Seventy-three of the invasive cancers (27.9%) received neoadjuvant chemotherapy. The mean resection weight was 177 grams. The mean pathological tumor size was 26 mm (range 0-180 mm) and varied from 23 mm (4-180 mm) for invasive cancers to 32 mm (0-100 mm) for DCIS. Specimen margins were involved in 12.6% of the cases; 10.5% of invasive ductal, 14.7% of DCIS, and 20.9% of invasive lobular. The overall breast conservation rate was 92% and varied from 87.4% for DCIS to 93.5% for the invasive cancers. Thirty-one patients (8.9%) developed one or more postoperative complications, inducing a delay in postoperative treatments in 4.6% of patients. The median follow up was 55 months. The cumulative 5-year incidences for local, regional, and distant recurrences were 2.2%, 1.1%, and 12.4%, respectively. Conclusions: Oncoplastic breast reductions allow wide resections with free margins and can be used for large cancers as an alternative to mastectomy.

KW - breast cancer

KW - breast conserving surgery

KW - complications

KW - local recurrence

KW - oncoplastic surgery

KW - survival

KW - therapeutic mammoplasty

KW - treatment delay

UR - http://www.scopus.com/inward/record.url?scp=85050246041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050246041&partnerID=8YFLogxK

U2 - 10.1097/SLA.0000000000002255

DO - 10.1097/SLA.0000000000002255

M3 - Article

AN - SCOPUS:85050246041

VL - 268

SP - 165

EP - 171

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 1

ER -